StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)

Close on Nov 17, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Monte Rosa Therapeutics's EV/EBITDA was 103.0× on Jan 30, 2026.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 2026103.0×+35.1
2025Dec 31, 202567.9×–

More Monte Rosa Therapeutics figures

See a number that looks wrong?